Jaguar Health, Inc. — Form 8-K Summary
Business Context and Reporting Period
Jaguar Health, Inc. filed a Form 8-K dated September 23, 2026, reporting privately negotiated debt-for-equity exchanges with Streeterville Capital, LLC. The filing concerns the Company’s secured promissory notes issued in 2021 and 2025.
Key Financial and Capitalization Metrics
| Item | Amount |
|---|---|
| 2021 Note balance reduction | $1,678,320 |
| Shares issued for 2021 Note exchange | 182,091 common shares |
| 2025 Note balance reduction | $5,049,909.26 |
| Shares issued for 2025 Note exchange | 547,898 common shares |
| Total debt reduction disclosed | $6,728,229.26 |
| Common shares outstanding as of September 24, 2026 | Approximately 1,463,958 |
The filing does not provide revenue, profit, cash flow, operating margin, cash balance, liquidity, or other income-statement metrics.
Material Changes Versus the Prior Comparable Period
- The 2021 Note’s outstanding balance was reduced by $1,678,320 in exchange for 182,091 shares.
- The 2025 Note was exchanged for 547,898 shares representing a $5,049,909.26 reduction; the 2025 Note was fully paid and cancelled upon completion.
- The transactions issued an aggregate of 729,989 shares, increasing equity capitalization and potentially diluting existing shareholders.
- The filing does not state the remaining balance of the 2021 Note after the exchange.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance or operating outlook was provided.
- The transactions reduced secured debt but involved substantial issuance of common stock relative to the approximately 1.464 million shares outstanding reported as of September 24, 2026.
- The 2021 Note exchange shares were issued without registration in reliance on the Securities Act Section 3(a)(9) exemption.
- The exchange agreements contain customary representations, warranties, and covenants. The filing does not provide the complete terms of the agreements beyond the disclosed description.
Investor Verification Items
- Verify the final outstanding balance and remaining terms of the 2021 Note.
- Review the filed 2021 Note Exchange Agreement for covenants, representations, and settlement mechanics.
- Reconcile the 729,989 shares issued with the reported 1,463,958 shares outstanding and assess resulting dilution.
- Confirm the accounting treatment and any gain, loss, or non-cash expense associated with the debt exchanges.
- Assess the Company’s post-transaction liquidity, secured debt, and financing needs, which are not disclosed in this filing.